Log in

OTCMKTS:KHTRFKnight Therapeutics Stock Price, Forecast & News

$5.59
+0.12 (+2.16 %)
(As of 06/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.59
Now: $5.59
$5.59
50-Day Range
$4.93
MA: $5.41
$5.69
52-Week Range
$3.44
Now: $5.59
$6.68
Volume775 shs
Average Volume4,054 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; Mytesi for symptomatic relief of noninfectious diarrhea in adult patients with HIV or AIDS on ART; and NERLYNX for the treatment of HER2-positive breast cancer. The company also develops Probuphine to treat opioid addiction; NeurAxon family for acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; AzaSite for bacterial conjunctivitis; Iluvien to treat diabetic macular edema; Netildex for ocular inflammation; 60P family to treat tropical diseases; Advaxis family to treat HPV-associated cancers and others; Triumvira family, a novel T-cell therapies for cancer; and TX-004HR for moderate-to-severe dyspareunia and TX-001HR for moderate-to-severe vasomotor symptoms due to menopause. In addition, it develops FLEXISEQ for pain and joint stiffness associated with osteoarthritis; Crescita family dermo-cosmetic line of products; Arakoda, a prevention of malaria; and Tenapanor for hyperphosphatemia treatment. Further, the company develops TULSA-PRO, a medical device for prostate ablation. Additionally, it finances other life science companies; and invests in life sciences venture capital funds. The company is headquartered in Montreal, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:KHTRF
CUSIPN/A
CIKN/A
Phone(514) 484-4483

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees48
Next Earnings DateN/A
OptionableNot Optionable

Receive KHTRF News and Ratings via Email

Sign-up to receive the latest news and ratings for KHTRF and its competitors with MarketBeat's FREE daily newsletter.

Knight Therapeutics (OTCMKTS:KHTRF) Frequently Asked Questions

How has Knight Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Knight Therapeutics' stock was trading at $4.7934 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, KHTRF stock has increased by 16.6% and is now trading at $5.5901. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Knight Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Knight Therapeutics.

What price target have analysts set for KHTRF?

1 brokers have issued 1-year price targets for Knight Therapeutics' shares. Their forecasts range from $10.30 to $10.30. On average, they anticipate Knight Therapeutics' share price to reach $10.30 in the next twelve months. This suggests a possible upside of 84.3% from the stock's current price. View analysts' price targets for Knight Therapeutics.

Has Knight Therapeutics been receiving favorable news coverage?

Media coverage about KHTRF stock has been trending very negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Knight Therapeutics earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutKnight Therapeutics.

Who are some of Knight Therapeutics' key competitors?

Who are Knight Therapeutics' key executives?

Knight Therapeutics' management team includes the following people:
  • Mr. Jonathan Ross Goodman B.A., L.L.B., M.B.A., BA, LLB, MBA, Founder, CEO & Director (Age 50)
  • Ms. Samira Sakhia C.A., C.P.A., M.B.A., MBA, BCom, CPA, DPA, CA, Pres, CFO & Director (Age 50)
  • Mr. Michel Loustric, Pres of Knight Barbados
  • Ms. Jody Engel, Director of Bus. Devel.
  • Ms. Amal Khouri, VP of Bus. Devel.

What is Knight Therapeutics' stock symbol?

Knight Therapeutics trades on the OTCMKTS under the ticker symbol "KHTRF."

How do I buy shares of Knight Therapeutics?

Shares of KHTRF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Knight Therapeutics' stock price today?

One share of KHTRF stock can currently be purchased for approximately $5.59.

What is Knight Therapeutics' official website?

The official website for Knight Therapeutics is www.gud-knight.com.

How can I contact Knight Therapeutics?

The company can be reached via phone at (514) 484-4483.

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.